MedTrace Logo

KN046 in Patients With Advanced Non-small Cell Lung Cancer

NCT03838848 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-03-02

No results posted yet for this study

Summary

This is a phase II, open label, multicenter study in subjects with advanced non-small cell lung cancer.

Conditions

  • Stage IV Non-small Cell Lung Cancer

Interventions

DRUG

KN046

3mg/kg, Q2W, intravenous injection (IV)

DRUG

KN046

5mg/kg, Q2W, intravenous injection (IV)

DRUG

KN046

5mg/kg, Q3W, intravenous injection (IV)

DRUG

Carboplatin

AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.

DRUG

Pemetrexed

500 mg/m2, Q3W, intravenous injection (IV)

DRUG

Ningetinib

Oral, QD

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou, MD · Shanghai Pulmonary Hospital, Shanghai, China

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-05
Primary Completion
2022-07-30
Completion
2022-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03838848 on ClinicalTrials.gov